Budesonide treatment for microscopic colitis from immune checkpoint inhibitors.

Secondary endpoint assessment Less than half of each cohort was admitted for enterocolitis symptoms; although patients with non-microscopic colitis were admitted more often, this did not reach statistical significance (microscopic colitis: 2/13, 15.4%; non-microscopic colitis: 11/25, 45.0%; p = 0.148).

also in 111,027 other papers